The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Highlights in AML from ASH 2025: menin inhibitors and ELN guidelines on MRD detection
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses highlights in acute myeloid leukemia (AML) from ASH 2025. She mentions the focus on menin inhibitors and the upcoming publication of the European LeukemiaNet (ELN) guidelines for measurable residual disease (MRD) detection. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this year at ASH, really the focus has been on menin inhibitors for AML, which are of course very exciting, really excited to see the data. I think the other really interesting thing, there was a session yesterday on guidelines on AML MRD detection, which is really nice. I know the paper on the ELN guidelines for MRD detection for AML are going to be out very soon, probably in the next issue of Blood...
I think this year at ASH, really the focus has been on menin inhibitors for AML, which are of course very exciting, really excited to see the data. I think the other really interesting thing, there was a session yesterday on guidelines on AML MRD detection, which is really nice. I know the paper on the ELN guidelines for MRD detection for AML are going to be out very soon, probably in the next issue of Blood. And so we heard from Dr Hausner yesterday his data on that, which is really exciting, really great. I’m really excited to use it. So a lot going on with AML and MDS. And I think this is particularly important. I think the data presented at this ASH is particularly important as we are working to refine the diagnostic criteria for AML and MDS and other myeloid neoplasms. So we will use this data very eagerly to inform the next classification.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
